The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection

Journal of Heart and Lung Transplantation

Volumn 35, Issue 9, 2016, Pages 1059-1066

  Clerkin, Kevin J ^a   Restaino, Susan W ^a   Zorn, Emmanuel ^a   Vasilescu, Elena R ^a   Marboe, Charles C ^a   Mancini, Donna M ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

antibody mediated rejection; cardiac allograft vasculopathy; donor specific antibodies; graft dysfunction; mortality

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY;

ADULT; AGE; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; COHORT ANALYSIS; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; DEATH; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RETRANSPLANTATION; RETROSPECTIVE STUDY; SEX; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; UNIVERSITY HOSPITAL; ALLOGRAFT;

ALLOGRAFTS; ANTIBODIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; RETROSPECTIVE STUDIES;

EID: 84979573673     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.04.007     Document Type: Article

References (16)

1. 1 Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report-2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 34 (2015), 1244–1254.
2. 2 Takemoto, S.K., Zeevi, A., Feng, S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 (2004), 1033–1041.
3. 3 Michaels, P.J., Espejo, M.L., Kobashigawa, J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 (2003), 58–69.
4. 4 Reed, E.F., Demetris, A.J., Hammond, E., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25 (2006), 153–159.
5. 5 Kfoury, A.G., Renlund, D.G., Snow, G.L., et al. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 28 (2009), 51–57.
6. 6 Coutance, G., Ouldamar, S., Rouvier, P., et al. Late antibody-mediated rejection after heart transplantation: Mortality, graft function, and fulminant cardiac allograft vasculopathy. The Journal of Heart and Lung Transplantation 34 (2015), 1050–1057.
7. 7 Hodges, A.M., Lyster, H., McDermott, A., et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 93 (2012), 650–656.
8. 8 Berry, G.J., Burke, M.M., Andersen, C., et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 32 (2013), 1147–1162.
9. 9 Mehra, M.R., Crespo-Leiro, M.G., Dipchand, A., et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy—2010. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 29 (2010), 717–727.
10. 10 Mickey, R.M., Greenland, S., The impact of confounder selection criteria on effect estimation. American journal of epidemiology 129 (1989), 125–137.
11. 11 Almuti, K., Haythe, J., Dwyer, E., et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation 84 (2007), 498–503.
12. 12 Loupy, A., Toquet, C., Rouvier, P., et al. Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association with Antibody-Mediated Rejection. American Journal of Transplantation 16 (2016), 111–120.
13. 13 Eisen, H.J., Tuzcu, E.M., Dorent, R., et al. Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. New England Journal of Medicine 349 (2003), 847–858.
14. 14 Jin, Y.P., Valenzuela, N.M., Ziegler, M.E., Rozengurt, E., Reed, E.F., Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am J Transplant 14 (2014), 806–819.
15. 15 Kobashigawa, J.A., Pauly, D.F., Starling, R.C., et al. Cardiac Allograft Vasculopathy by Intravascular Ultrasound in Heart Transplant patients Substudy From the Everolimus Versus Mycophenolate Mofetil Randomized, Multicenter Trial. JACC: Heart Failure 1 (2013), 389–399.
16. 16 Mancini, D., Pinney, S., Burkhoff, D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003), 48–53.